chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information was received 30-JUN-2017 via a phone call from a licensed practical nurse who reported that a patient (age and gender not specified) was administered an improperly stored dose of PNEUMOVAX 23 on an unspecified date. Lot number and expiration date were not provided. No adverse effects were reported. No additional information was provided. This is one of several cases from the same reporter. Additional information was requested. Sender's Comments: US-009507513-1707USA009865: US-009507513-1707USA009867: US-009507513-1707USA009868: US-009507513-1707USA009869: US-009507513-1707USA005581.
Dizziness immediately after the shot. Approximately 12 hours after the shot, I started having a fever, body aches, and headache. My symptoms lasted for approximately 36 hours. This was my first covid vaccine shot. I had a moderate case of covid 4 months before getting the vaccine.
Itchy red bumpy rash around neck, stomach and back.; Itchy red bumpy rash around neck, stomach and back.; Itchy red bumpy rash around neck, stomach and back.; first dose 30Apr2021, second dose on 11Jun2021; This is a spontaneous case received from a contactable consumer (patient). A 49-year-old non-pregnant female patient received second dose of bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EW0217), via an unspecified route of administration, administered in left arm on 11Jun2021 at 14:00 as DOSE 2, SINGLE and first dose of bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: ER8736), via an unspecified route of administration, administered in left arm on 30Apr2021 as DOSE 1, SINGLE (age at vaccination 49-year-old) for COVID-19 immunization. The patient was not pregnant at the time of vaccination. The patient medical history included hypothyroid. Concomitant medications included anti-anxiety and thyroid meds. The patient previously took erythromycin and experienced allergies. Prior vaccination within 4 weeks was reported as none. On 14Jun2021, the patient experienced itchy red bumpy rash around neck, stomach and back. The patient reported that the events happened with the first vaccine as well. The patient was administered inappropriate schedule of vaccine. The patient did not receive any treatment for the event. COVID prior vaccination and COVID tested post vaccination was reported as none. The outcome of the events was recovering.  Follow-Up (02Aug2021): Follow-up attempts are completed. No further information is expected.
p/vax pt devel rash on 8/15/99 w/between 50-500 pox;no complications;no meds given;no fever, no antipyretics given;
Information has been received from a respiratory therapist concerning a female patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23 (lot # 659922/1667U) expiration date on 23-AUG-2009. On an unspecified date after received the vaccine, she developed low grade fever and pain at the injection site. The symptoms lasted about 24-48 hours. The patient sought medical attention by telephone. At the time on the report on 06-JUL-2009 the patient was recovering. There were no laboratories diagnostics studies performed. The reporter requested a lot check. A lot check has been initiated. Follow up information has been received from a respiratory therapist concerning the 75 year old female with elevated blood pressure at the time of vaccination; cardiac murmur and constipation started on 11-JUL-2007; ataxia started on 13-NOV-2007; hyperactive bladder, rhinitis allergic and localized primary osteoarthritis of the right knee started on 25-JUL-2008; epistaxis started on 20-AUG-2008; oesophageal reflux, fatigue, ganglion of the right wrist, osteopenia, hyperlipidaemia started on 03-FEB-2009; haematuria started on 17-FEB-2009; pollakiuria started on 26-MAY-2009; osteopenia started on 12-JUN-2009; benign essential hypertension started on 02-JUL-2009 who on 02-JUL-2009 at 09:30 a.m. was vaccinated intramuscularly into left deltoid with first dose of PNEUMOVAX 23 (lot # 659922/1667U). Concomitant therapy included aspirin, Q-10, H2OFF, multivitamins oral tablet, OCUVITE, oxybutyninCl, RESTASIS, simvastatin (manufacturer unknown) and ascorbic acid, CALTRATE-D, lisinopril (manufacturer unknown), and vitamin D. On 02-JUL-2009, she started on therapy with alendronate sodium (MSD) (70mg once weekly). On 02-JUL-2009, in the morning, the patient experienced tenderness at the injection site and low grade of fever, and achiness, a couple of days for each. On 05-JUL-2009, the patient recovered from tenderness at injection site, low grade of fever and achiness. A standard lot check investigation was performed. All in-process quality checks for the lot number 659922/1667U were satisfactory. The lot met the requirements and was released. Follow up information has been received via telephone call from a respiratory therapist who verified that the form sent was a listing of the patient's current health issues for evaluation. All the conditions listed on this form were pre-existing conditions and were present at the time of the patient's vaccination. None of the problems listed began after the patient was vaccinated with PNEUMOVAX 23. This is one of four reports from the same source. Additional information is not expected.
Soreness at the site, muscle weakness, muscle pain. Patient saw her PCP - Dr. who gave her prednisone. Pt told me that she thinks it's getting better Dr said pt was sensitive to the vaccine.
Mother stated that 3 hours after vaccine, she noticed a red spot with raised bumps approximately 1 1/2 inches across at injection site. Reaction began to fade 2 hours after that. No treatment was rendered.
6 DAYS AFTER VACCINATION DEVELOPED  ERYTHEMA  MULTIFORME AND FEVER.
Flu like symptoms starting the day after the vaccine. Muscle and joint ache and pain. Bruising and fever in left bicep that continued for 4 days before clearing.
chest congestion; stuck up sinus; Allergic reaction; coughing; mucus in nose and throat; headaches; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RESPIRATORY TRACT CONGESTION (chest congestion), SINUS CONGESTION (stuck up sinus), HYPERSENSITIVITY (Allergic reaction), COUGH (coughing) and NASAL CONGESTION (mucus in nose and throat) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Prostatic disorder (Prostate Problem).    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, the patient experienced RESPIRATORY TRACT CONGESTION (chest congestion), SINUS CONGESTION (stuck up sinus), HYPERSENSITIVITY (Allergic reaction), COUGH (coughing), NASAL CONGESTION (mucus in nose and throat) and HEADACHE (headaches). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of 1 dosage form. At the time of the report, RESPIRATORY TRACT CONGESTION (chest congestion), SINUS CONGESTION (stuck up sinus), HYPERSENSITIVITY (Allergic reaction), COUGH (coughing), NASAL CONGESTION (mucus in nose and throat) and HEADACHE (headaches) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant Medication reported by reporter. His HCP  stated that for patient receiving the vaccine brought up allergies. Patient is starting to get better.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-192952 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
74-year-old female with cardiac risk factors presents with exertional dyspnea over the past 3 days.  Patient had low oxygen saturation 81% at the doctor's office which came up to 89 with rest.  Patient placed on oxygen here in the emergency department.  Patient does not have symptoms at rest.  Patient does not have any calf swelling or pleuritic pain. Patient's D-dimer is elevated therefore CT angio of the chest was obtained which shows large, central pulmonary embolism with evidence of right heart strain.
The vaccine is not permitted for patients under the age of 18.  Patient was scheduled for a dose and the nurse (myself) overlooked the age of the patient.
This spontaneous report as received from a certified medical assistant refers to an unspecified number of patients of unknown age and gender. On 16-JUL-2014, the patients were vaccinated with doses of VARIVAX (Merck) (lot # J012377 exp date 03-OCT-2015 also reported as 08-NOV-2014) (dose not reported) subcutaneously that were improperly exposed to 7 degrees C from 13-MAY-2014 to 16-JUL-2014. No known adverse effects were reported. This is one of several reports received from the same source. Additional information is not expected. All follow ups requested to completed the case were received.
After vaccine administration, patient sat back and fainted. He was out for under one minute but had multiple tremors.
Developed redness pain swelling at injection site and down arm.  Fever to 102.
Approximately 4-5 hours post vaccination, client states she noticed redness over entire face and bilateral upper arms. Client states area of redness had burning sensation with touch. Client states similar to sunburn. Client states resolved approximately 24 hours after she first noticed the redness.
got SHINGLES way after the shot / suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional case details were reported as follows: The reporter was patient itself. The age at vaccination was not reported. The patient got Shingles way after the shot. The patient stated hope they had something better out there now. This case was considered as suspected vaccination failure, as details regarding completion of primary vaccination schedule, laboratory test confirmation and time to onset for shingles were unknown at the time of reporting. The follow up was not required.
A few days after COVID19 vaccine administration on the patient's L arm he developed a L eye stye and a new L upper lip herpes labias outbreak, patient has a history of cold sores in the past. Patient applied topical abreva to the cold sore which he has used in the past resulting in upper lip swelling. Unclear if the upper lip swelling is a result of the abreava or delayed from the vaccine.
Numbness in left arm and tingling. Treated with ice packs. Dizziness started within 2 hours. Sore arm. Dizziness lasted x 24 hours. Nausea day after vaccine. Noticed facial swelling: non-erythmatous at buccal nodes bilat next day after vaccine at 24-hour mark.  Still with some swelling of lymph nodes facial/buccal nodes as of 11/17/2021.  No itching. No shortness of breath.
Day of: No noticeable adverse events recalled. Possible long term adverse effects: development of acquired condition of antiphospholipid antibodies due to fetal phospholipids possibly contained in the RA27/3 rubella vaccine that was administered.  The antiphospholipid antibodies have caused symptoms in patient during pregnancy only.  Symptoms have included: recurring miscarriages, clots in placenta during pregnancy which resulted in near fatal HELLP syndrome condition in pregnancy.  HELLP went unnoticed because patient did not have high BP and did not have protein in urine even on day of emergency c-section.  Patient possibly developed auto-antibodies to other fetal proteins contained in RA27/3 vaccine which produced additional symptoms during pregnancy as follows: 8-10 vomit sessions per day in 1st trimester of HELLP pregnancy; 5-6 vomit sessions per day in 2nd trimester; 1-2 vomit sessions per day up to 34 weeks; throughout entire pregnancy, every day there was extreme flu-like symptoms with inability to eat, drink, keep any food down, work or perform normal functions; foaming at mouth during all waking hours began at 12 weeks and continued to 22 weeks, the consistency of the mouth foam was that of egg whites whipped to medium peaks, white spots covered inside of mouth and tongue, extreme indigestion despite minimal food intake.  Patient is extremely healthy, physically active and a productive working citizen in a non-pregnant state.  At least 1 miscarriage post HELLP pregnancy and 2-3 prior. No, patient has long-term and permanent immune-mediated reproductive problems, as evidenced by amnastic immune effect whereby pregnancy 1 produced near death HELLP Syndrome and emergency C-section at 34 wks, pregnancy 2 miscarried at 8.5 weeks and pregnancy 3 miscarried at 6 weeks. One early miscarriage occurred before HELLP pregnancy. Patient believes her CD4 memory T-cells are reacting to a pregnancy specific/ fetal-specific/ placental or amniotic specific peptide as a result of this vaccine which used multiple products of the female reproductive tract in attenuating, amplificatio of the live viruses contained. The CD4 memory T-cells are getting faster and more efficient at eliminating the pregnancies which are interpreted as antigenic.
I had Edema on my right breast and lymphadenopathy on the right side. I experienced fatigue and loss of appetite lasting for two weeks. Due to the ice storm I wasn't able to seek treatment I discussed everything over the phone with my doctor.
First Covid vaccine 2/19/2021,  Lichen Sclerosis  started on 2/20 and visually diagnosed on 2/23/2021.  Now using  Clobetasol ointment daily until  3/23 then switch to every other day, possibly forever.  I had one episode of Lichen Sclerosis 5 years with no other repeat episode.  It is calming down now.  Genital Herpes  started about 3/4-5/2021 and diagnosed visually by Dr.  She also performed a swab culture to confirm.   Now using  Acyclovir  daily.  It is calming down.  The only flare up I have had before was 40 years age, no repeat inflammation since then.   My second shot was 3/12.
Since patient received her Fluzone HD and Pneumovax 23 immunizations in her left arm, her arm became tender from the shoulder to the elbow and she has developed a reddened area across the middle of her upper arm which is warm to touch.  This red area is about four inches below the injection sites.
Delayed injection site reaction; Hot to touch injection site; Chills on and off; Injection site puffy,red; Red at injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of SKIN REACTION (Delayed injection site reaction), VACCINATION SITE WARMTH (Hot to touch injection site), CHILLS (Chills on and off), VACCINATION SITE SWELLING (Injection site puffy,red) and VACCINATION SITE ERYTHEMA (Red at injection site) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 29-Dec-2020, the patient experienced VACCINATION SITE ERYTHEMA (Red at injection site). On 07-Jan-2021, the patient experienced SKIN REACTION (Delayed injection site reaction), VACCINATION SITE WARMTH (Hot to touch injection site), CHILLS (Chills on and off) and VACCINATION SITE SWELLING (Injection site puffy,red). At the time of the report, SKIN REACTION (Delayed injection site reaction), VACCINATION SITE WARMTH (Hot to touch injection site), CHILLS (Chills on and off), VACCINATION SITE SWELLING (Injection site puffy,red) and VACCINATION SITE ERYTHEMA (Red at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information include antihistamines.
I do not know where I was exposed to COVID-19 but I was at an outdoor event and in contact with a lot of people, but I have no idea where I got it. I first had a runny nose and cough. I could tell that I was more sick than just a regular cold. The symptoms were not very bad but enough that I could tell that this was different. I was supposed to fly internationally 5 days later but I rescheduled that flight before I even got test results. I took multiple home tests that were negative. I took a PCR test at a local pharmacy on 06/30/2022. I received  positive results a few days later. I experienced a severe lack of energy. I had one day of a really bad headache. I did not have any fever but did have sore throat, some coughing, and night sweats. I was very relieved that it did not move into my lungs due to my existing asthma. I had a telehealth visit and was prescribed Paxlovid and began taking it on 07/02/2022. I took my last dose on the morning of 07/06/2022. After beginning the medication, cough, sore throat, and runny nose only lasted 1-3 days. My headache had already improved before beginning the Paxlovid. The lack of energy lasted for around 2 weeks after the onset of my symptoms.
Patient described having a "Hot Flash" and then felt short of breath. Listened to patients breath sounds. They were clear to auscultation. Offered to call 911, she declined. Gave patient dose of benedryl and had her sit for approx 5-10 minutes. Patient then stated going back to her office. Checked back in with patient 30 minutes later, stated she felt better.
pt devel nausea & vomiting 2 days p/vax;pt came to tx room on 10/24/98;phenergan tablets given;
Vaccination site swelling; 99.8 degrees concerned; Extreme Fatigue; Body ache, soreness; injection site has redness that is 2 " in diameter; pain at injection site; This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 11-Jul-2021. The most recent information was received on 29-Jul-2021 and was forwarded to Moderna on 29-Jul-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site has redness that is 2 " in diameter), PYREXIA (99.8 degrees concerned), VACCINATION SITE PAIN (pain at injection site), FATIGUE (Extreme Fatigue) and MYALGIA (Body ache, soreness) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 052C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (sulfa drugs) and Penicillin allergy.    On 07-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jul-2021, the patient experienced VACCINATION SITE PAIN (pain at injection site). On 08-Jul-2021, the patient experienced VACCINATION SITE ERYTHEMA (injection site has redness that is 2 " in diameter), FATIGUE (Extreme Fatigue) and MYALGIA (Body ache, soreness). On 10-Jul-2021, the patient experienced PYREXIA (99.8 degrees concerned). On 11-Jul-2021, the patient experienced VACCINATION SITE SWELLING (Vaccination site swelling). The patient was treated with PARACETAMOL (TYLENOL) on 07-Jul-2021 for Pain, at a dose of 1 dosage form and CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) on 11-Jul-2021 at a dose of 1 dosage form. On 21-Jul-2021, VACCINATION SITE ERYTHEMA (injection site has redness that is 2 " in diameter), PYREXIA (99.8 degrees concerned), VACCINATION SITE PAIN (pain at injection site), FATIGUE (Extreme Fatigue), MYALGIA (Body ache, soreness) and VACCINATION SITE SWELLING (Vaccination site swelling) had resolved with sequelae.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.8 (High) 99.8.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Allergies to food, and other products Concomitant medications were not provided.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Significant Follow up received - Updated the vaccine details like Batch/Lot number and vaccination site, New Events  vaccination site pain, extreme fatigue, Myalgia and Vaccination site swelling added. Outcome updated from unknown to recovered with sequalae.
18 hour after the shot, my lip suddenly swelled and my Blood pressure when up to 212/113.  It normally runs at 110/80 and was just checked at a doctors office last week. I was in the ER for 10 hours.  (waiting most of this time).  They got my BP do come down some, but it has been running 170/100 for the past week, which is way outside normal
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2022 at 2:41 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 28-Jan-2022 at 2:41 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-JAN-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient ethnicity reported . Concomitant products were not provided. Treatment medications were not reported.  Patient received booster dose vaccination time was reported as 14:41:17. This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022.   This case was linked to MOD-2022-542869 (Patient Link).
Fever 102.3 lasted 24 hours , Headache 3 days . Head pressure when lowering head . Arm pit glands swollen and painful
Narrative: 23-year-old male with a PMH of ADHD who reported to his primary care provider signs/symptoms of headache, low grade fever of 100.1F, headache and rash on both arms a day after receiving J&J COVID-19 vaccine, The patient took 2 tablets of Tylenol and was advised by the provider to take diphenhydramine and continue support care. the patient declined getting tested for COVID 19 and agreed with the treatment plan. No other information available after that phone encounter.